Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

Share:
Related ABT
5 Biggest Price Target Changes For Friday
12 Stocks To Watch For July 20, 2017
First Citizens Bank & Trust Co Buys iShares Core S&P Mid-Cap, Baxter International Inc, ... (GuruFocus)

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).

Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”

Abbott Laboratories closed on Friday at $65.53.

Latest Ratings for ABT

DateFirmActionFromTo
Jul 2017ArgusMaintainsBuy
Jul 2017Deutsche BankMaintainsBuy
Jul 2017Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!